| pubmed-article:7678709 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0220847 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0005768 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0005795 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0000768 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0001899 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C1511790 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C1521828 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C1705241 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C0205473 | lld:lifeskim |
| pubmed-article:7678709 | lifeskim:mentions | umls-concept:C1705242 | lld:lifeskim |
| pubmed-article:7678709 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7678709 | pubmed:dateCreated | 1993-2-24 | lld:pubmed |
| pubmed-article:7678709 | pubmed:abstractText | The serologic reactivity and epidemiology associated with different hepatitis C virus (HCV) variants were investigated in a cohort of 113 anti-HCV-positive donors. In Scotland, HCV type 1 accounted for one-half of all infections; 40 percent of subjects were infected with HCV type 3, and the remainder were infected with type 2. Reactivity with the NS-4-encoded antigens in the first-generation anti-c100 assay was absent in 68 percent of donors infected with types 2 and 3, as compared with 10 percent for those infected with type 1. Even when combined with surrogate marker testing, first-generation tests would have failed to detect 12 percent of HCV-infected blood donors. The age distribution, incidence of past infection with hepatitis B virus, and reported risk factors were similar in donors infected with types 1 and 3 (mean ages were 31.9 and 29.9; 18 and 17.5% were positive for antibody to hepatitis B core antigen; and 47 and 48% had past intravenous drug abuse). However, the distributions of alanine aminotransferase levels were significantly different in those infected with type 3 (abnormally raised in 83%) and those infected with type 1 (55% abnormal alanine aminotransferase; p < 0.05) or type 2 (60%; p < 0.01) and those who were nonviremic (8%; p < 0.0001). These data suggest that HCV type 1 is the most common HCV infection in blood donors and that infection with HCV type 3 may be associated with more severe liver disease, because of more recent infection or because of a greater inherent pathogenicity of type 3 variants. | lld:pubmed |
| pubmed-article:7678709 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7678709 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7678709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7678709 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7678709 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:7678709 | pubmed:issn | 0041-1132 | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:FollettE AEA | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:YamP APA | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:CrawfordR JRJ | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:CoxC BCB | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:ChanS WSW | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:GillonJJ | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:SimmondsPP | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:McOmishFF | lld:pubmed |
| pubmed-article:7678709 | pubmed:author | pubmed-author:FrameW DWD | lld:pubmed |
| pubmed-article:7678709 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7678709 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:7678709 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7678709 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7678709 | pubmed:pagination | 7-13 | lld:pubmed |
| pubmed-article:7678709 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:meshHeading | pubmed-meshheading:7678709-... | lld:pubmed |
| pubmed-article:7678709 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:7678709 | pubmed:articleTitle | Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. | lld:pubmed |
| pubmed-article:7678709 | pubmed:affiliation | Edinburgh and South East Scotland Blood Transfusion Service. | lld:pubmed |
| pubmed-article:7678709 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7678709 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7678709 | lld:pubmed |
